Skip to main content

Table 6 Evolution of rates of resistance to colistin and tobramycin in ICU, by 1000 days

From: Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance

  Resistance Period
1st year 2nd year 3rd year 4th year
(n = 59) (n = 56) (n = 69) (n = 101)
Patient-days   9228 8583 10,731 9315
Colistin At admission 5 (8.5) 17 (30.4) 30 (43.5) 61 (60.4)
  Acquired in ICU 3 (5.1) 8 (14.3) 7 (10.1) 12 (11.9)
  Acquired in ICU, by 1000 days 0.325 0.932 0.652 1.288
  Acquired in ICU, by 1000 days and adjusted by rate of resistance at admissiona 0.278 0.228 0.187 0.153
Tobramycin At admission 17 (6.0) 32 (11.2) 34 (11.9) 68 (23.9)
  Acquired in ICU 1 (0.4) 3 (1.1) 15 (5.3) 11 (3.9)
  Acquired in ICU, by 1000 days 0.108 0.350 1.398 1.181
  Acquired in ICU, by 1000 days and adjusted by rate of resistance at admissiona 0.144 0.162 0.182 0.205
  1. ICU Intensive care unit
  2. The increasing rate of colistin- and tobramycin-acquired colonization resistance in the ICU by 1000 days and adjusted by the rate of resistance at admission was 0.82 (95% CI, 0.56 to 1.95; not statistically significant [NS]). P value for the goodness-of-fit test was 0.427. For tobramycin, the increasing rate was 1.13 (95% CI, 0.75 to 1.70; nonsignificant). P value for the goodness-of-fit test was 0.159
  3. aAdjusted for values corresponding to first year, namely number of patients, number of resistances at admission, and exposure days